共 50 条
- [21] R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruziACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (04): : 434 - 439Choi, Jun YongCalvet, Claudia M.Vieira, Debora F.Gunatilleke, Shamila S.Cameron, Michael D.McKerrow, James H.Podust, Larissa M.Roush, William R.
- [22] Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51 as Anti-Chagas AgentsJOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (19) : 7651 - 7668Choi, Jun YongCalvet, Claudia M.Gunatilleke, Shamila S.Ruiz, ClaudiaCameron, Michael D.McKerrow, James H.Podust, Larissa M.Roush, William R.
- [23] Complexes of Trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease STRUCTURAL BASIS FOR PATHOGEN SELECTIVITYJOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (44) : 31602 - 31615Hargrove, Tatiana Y.Wawrzak, ZdzislawAlexander, Paul W.Chaplin, Jason H.Keenan, MartineCharman, Susan A.Perez, Catherine J.Waterman, Michael R.Chatelain, EricLepesheva, Galina I.
- [24] Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and developmentSCIENTIFIC REPORTS, 2014, 4 : 1 - 11Moraes, Carolina B.Giardini, Miriam A.Kim, HwayoungFranco, Caio H.Araujo-Junior, Adalberto M.Schenkman, SergioChatelain, EricFreitas-Junior, Lucio H.
- [25] Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and developmentScientific Reports, 4Carolina B. MoraesMiriam A. GiardiniHwayoung KimCaio H. FrancoAdalberto M. Araujo-JuniorSergio SchenkmanEric ChatelainLucio H. Freitas-Junior
- [26] Derivatization of the interface cysteine of triosephosphate isomerase from Trypanosoma brucei and Trypanosoma cruzi as probe of the interrelationship between the catalytic sites and the dimer interfaceBIOCHEMISTRY, 1999, 38 (13) : 4114 - 4120Pérez-Montfort, RGarza-Ramos, GAlcántara, GHReyes-Vivas, HGao, XGMaldonado, Ede Gómez-Puyou, MTGómez-Puyou, A
- [27] 4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo PotencyJOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (16) : 6989 - 7005Calvet, Claudia M.Vieira, Debora F.Choi, Jun YongKellar, DanielleCameron, Michael D.Siqueira-Neto, Jair LageGut, JiriJohnston, Jonathan B.Lin, LiKhan, SusanMcKerrow, James H.Roush, William R.Podust, Larissa M.
- [28] Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas DiseasePLOS NEGLECTED TROPICAL DISEASES, 2015, 9 (09):Riley, JenniferBrand, StephenVoice, MichaelCaballero, IvanCalvo, DavidRead, Kevin D.
- [29] Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibitionFEBS LETTERS, 2014, 588 (21) : 3878 - 3885Cherkesova, Tatiana S.Hargrove, Tatiana Y.Vanrell, M. CristinaGes, IgorUsanov, Sergey A.Romano, Patricia S.Lepesheva, Galina I.
- [30] In Vitro and In Vivo Studies of the Antiparasitic Activity of Sterol 14α-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma cruziANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (09) : 4151 - 4163Correia Soeiro, Maria de Nazarede Souza, Elen Melloda Silva, Cristiane FrancaJaen Batista, Denise da GamaBatista, Marcos MeuserPavao, Beatriz PhilotAraujo, Julianna SicilianoFortes Aiub, Claudia Alessandrada Silva, Patricia BernardinoLionel, JessicaBritto, ConstancaKim, KwanghoSulikowski, GaryHargrove, Tatiana Y.Waterman, Michael R.Lepesheva, Galina I.